UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 19, 2015
Dendreon Corporation
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
|
001-35546 |
|
22-3203193 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
1301 2nd Avenue, Seattle, Washington |
|
98101 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (206) 256-4545
Not applicable.
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
As previously announced, on November 10, 2014, Dendreon Corporation (the Company) and its wholly owned subsidiaries, Dendreon
Holdings, LLC, Dendreon Distribution, LLC and Dendreon Manufacturing, LLC (collectively, together with the Company, the Debtors) filed voluntary petitions for relief (the Chapter 11 Cases) under Chapter 11 of Title 11 of the
United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (the Bankruptcy Court).
On November 9, 2014, as previously disclosed, the Debtors and (i) certain holders representing approximately 47.8% and
(ii) certain other holders representing approximately 35.9% of the outstanding principal amount of the Companys 2.875% Convertible Senior Notes due 2016 (the 2016 Notes) entered into two separate Plan Support Agreements (as
amended and restated, the PSAs). Under the terms of the PSAs, the parties agreed to work to effectuate a restructuring of the Debtors obligations pursuant to a stand-alone plan of reorganization in Chapter 11 under which holders of
the 2016 Notes would receive new shares of common stock in the reorganized Company, subject to the outcome of the competitive process contemplated in the PSAs (the Competitive Process). On December 17, 2014, the Bankruptcy Court
entered an order that, among other matters, established the bidding procedures (the Bidding Procedures) proposed to be employed with respect to the Competitive Process and established the deadline for submitting Qualified Bids (as
defined in the Bidding Procedures).
As previously disclosed, on January 29, 2015, the Debtors entered into an acquisition agreement
(the Original Stalking Horse Agreement) with Valeant Pharmaceuticals International, Inc. (Valeant), pursuant to which Valeant agreed to acquire substantially all of the assets and certain liabilities of the Debtors for $296
million in cash. On February 4, 2015, the Debtors and Valeant entered into an amended and restated acquisition agreement (the Amended Stalking Horse Agreement), which amended certain terms of the Original Stalking Horse Agreement
and provided for an aggregate purchase price of $400 million in cash. On February 19, 2015, the Debtors, Valeant and Drone Acquisition Sub Inc., a wholly-owned direct subsidiary of Valeant (the Purchaser), entered into a second
amended and restated acquisition agreement (the Acquisition Agreement), which amends certain terms of the Amended Stalking Horse Agreement and provides for an aggregate purchase price of $495 million (which includes the purchase of
$80 million in cash, for an effective increase of $15 million over the Amended Stalking Horse Agreement for the purchase of certain additional assets of the Debtors), of which $445.5 million is payable in cash at closing and $49.5 million
is payable in common shares of Valeant to be issued to the Company on the anticipated date of effectiveness of a plan of liquidation or reorganization in the Chapter 11 Cases and subsequently distributed to creditors in accordance with such plan and
the terms of the Acquisition Agreement. The Acquisition Agreement includes the Debtors assets related to their enteric coated D-3263 hydrochrolide product candidate, as well as $80 million of cash of the Debtors. The parties have agreed that
the Acquisition Agreement will constitute a plan of reorganization of the Company and the Purchaser for purposes of Sections 368 and 354 of the Internal Revenue Code of 1986, as amended (which plan includes the liquidation of the Company
and the distribution of the stock consideration).
The Acquisition Agreement is subject to a number of closing conditions, including
approval by the Bankruptcy Court; the absence of a governmental order or other legal prohibition related to the transaction; the accuracy of representations and warranties of the parties, subject to certain qualifications; and material compliance
with the obligations set forth in the Acquisition Agreement. In addition, in the event that the proposed sale order to be entered by the Bankruptcy Court in connection with the Acquisition Agreement is not entered, or the Bankruptcy Court advises
the parties during the hearing related to such order that such order will not be entered, on February 20, 2015 (which date is subject to extension to no later than February 24, 2015 in connection with certain force majeure events), the
Purchaser is entitled to terminate the Acquisition Agreement, in which case the rights and obligations of the parties under the Amended Stalking Horse Agreement will remain in full force and effective, and the parties will use commercially
reasonable efforts to obtain entry of the proposed sale order related to the Amended Stalking Horse Agreement on February 20, 2015.
The asset sale pursuant to the Agreement is being conducted under the provisions of Section 363 of the Bankruptcy Code. As previously
announced, the bid deadline provided by the Bidding Procedures expired on February 10, 2015 without receipt of additional Qualified Bids. The Acquisition Agreement calls for the Debtors to pay a break-up fee equal to $12 million and an expense
reimbursement amount not to exceed $1 million in certain circumstances, including if the Debtors consummate another sale or restructuring transaction with a third party.
The Debtors will file a Notice of Filing of Amended Acquisition Agreement and Proposed Sale Orders with the Bankruptcy Court related to the
filing of the Acquisition Agreement and the proposed sale orders with respect to the transactions contemplated by each of the Amended Stalking Horse Agreement and the Acquisition Agreement. Copies of such documents will be attached to such notice on
file with the Bankruptcy Court. On February 19, 2015, the Debtors manually delivered such notice to the Bankruptcy Court due to an unexpected shutdown of the Bankruptcy Courts electronic filing system, which prevented the electronic filing
thereof.
Cautionary Statement Regarding Forward-Looking Statements
Certain information in this Current Report may constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this Current Report that are not statements of historical fact, including statements regarding the satisfaction of conditions to the closing of the proposed asset sale, the potential of the proposed
asset sale and the expectation that the Chapter 11 filings will enable the Company to sell its assets in an orderly manner and maximize value for its stakeholders and other estimates, projections, future trends and the outcome of events that have
not yet occurred referenced in this Current Report should be considered forward-looking statements. Words such as anticipate, estimate, expect, project, intend, plan,
believe, may, predict, will, would, could, should, target and similar expressions are often used to identify forward-looking statements. Actual results
or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties, including, among others, the potential adverse impact of the Chapter 11 Cases on the Companys liquidity or results of
operations, changes in the Companys ability to meet financial obligations during the Chapter 11 process or to maintain contracts that are critical to the Companys operations, the outcome or timing of the Chapter 11 process and the
proposed asset sale (including the likelihood of consummating the proposed asset sale), the effect of the Chapter 11 Cases or proposed asset sale on the Companys relationships with third parties, regulatory authorities and employees,
proceedings that may be brought by third parties in connection with the Chapter 11 process or the proposed asset sale, Bankruptcy Court approval, regulatory approval or other closing conditions or termination events in connection with the proposed
asset sale, and the timing or amount of any distributions to the Companys stakeholders. For a discussion of some of the additional risks and important factors that the Company believes could cause actual results or events to differ from the
forward-looking statements that it makes, see the sections entitled Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in the Companys Quarterly Report on Form
10-Q for the quarter ended September 30, 2014. In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results or events
to differ from those contained in any forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking statements contained in this Current Report. Any forward-looking statements speak only as of the date of this
Current Report. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
Limitation on Incorporation by Reference
In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report is being furnished for
informational purposes only and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this Current Report will not be deemed an admission as to the materiality of any information required to be disclosed solely by
Regulation FD.
Additional Information Regarding the Chapter 11 Cases
Information about the Chapter 11 process, as well as court filings and other documents related to the reorganization proceedings, is available
through the Companys claims agent, Prime Clerk, at https://cases.primeclerk.com/dendreon or 844-794-3479. Information contained on, or that can be accessed through, such web site or the Bankruptcy
Courts web site is not part of this Current Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
DENDREON CORPORATION |
|
|
|
Date: February 19, 2015 |
|
By: |
|
/s/ Robert L. Crotty |
|
|
|
|
Name: |
|
Robert L. Crotty |
|
|
|
|
Title: |
|
Executive Vice President, General Counsel
and Secretary |